ASH 2022 | Real-world data on the safety of emicizumab in patients with hemophilia A
In this video, Francis Nissen, MD, PhD, Hoffmann-La Roche Ltd., Basel, Switzerland, summarizes real-world data from the European Haemophilia Safety Surveillance (EUHASS) database that assessed the incidence of thrombotic microangiopathies and thrombotic events in patients with hemophilia A (HA) treated with emicizumab. Dr Nissen also highlights other registries and databases evaluating the real-world safety and efficacy of emicizumab, which demonstrate that this agent is favorable with respect to thrombotic microangiopathies and events. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
F. Hoffmann-La Roche Ltd: Current Employment, Current holder of stock options in a privately-held company.
